<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font6" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font7" size="10" family="GillSans" color="#ffffff"/>
	<fontspec id="font8" size="10" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font9" size="10" family="GillSans" color="#000000"/>
	<fontspec id="font10" size="6" family="TARIJY+Helvetica,Bold" color="#000000"/>
	<fontspec id="font11" size="6" family="TARIJY+Helvetica,Bold" color="#000000"/>
	<fontspec id="font12" size="6" family="UKOTMN+Helvetica" color="#000000"/>
	<fontspec id="font13" size="5" family="UKOTMN+Helvetica" color="#000000"/>
<text top="41" left="55" width="132" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">BMC Nuclear Medicine 2005, 5 :7<i>BMC Nuclear Medicine</i></text>
<text top="41" left="373" width="181" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.biomedcentral.com/1471-2385/5/7</text>
<text top="756" left="503" width="51" height="10" font="font1" id="p1_t3" reading_order_no="112" segment_no="10" tag_type="text">Page 9 of 10<b>5</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="113" segment_no="11" tag_type="text">(page number not for citation purposes)</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="29" segment_no="7" tag_type="text">mal liver and therefore appear "hot" on an MAA perfusion</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="30" segment_no="7" tag_type="text">scan. Patient characteristics and tumour stage, grade and</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="31" segment_no="7" tag_type="text">extent do not appear to influence tumour vascularity as<i>(page number not for citation purposes)</i></text>
<text top="404" left="55" width="65" height="9" font="font4" id="p1_t8" reading_order_no="32" segment_no="7" tag_type="text">judged by TNR.</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="33" segment_no="8" tag_type="text">Early studies of internal radiation therapy reported that</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="34" segment_no="8" tag_type="text">patients with relatively avascular tumours, as demon-</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="35" segment_no="8" tag_type="text">strated by arteriography, did not respond as well as those</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="36" segment_no="8" tag_type="text">patients with moderately to highly vascular tumours</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="37" segment_no="8" tag_type="text">[18,19]. These studies, however, involved relatively small</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="38" segment_no="8" tag_type="text">numbers and included patients with a variety of different</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="39" segment_no="8" tag_type="text">primary cancers. Furthermore arteriography may not be a</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="40" segment_no="8" tag_type="text">particularly accurate way of assessing tumour blood flow.<a href="">[18,19]</a>. These studies, however, involved relatively small</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="41" segment_no="8" tag_type="text">The relationship between vascularity of CRC hepatic</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="42" segment_no="8" tag_type="text">tumours and response to HAC has been studied by a</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="43" segment_no="8" tag_type="text">number of groups. An early study by Kim et al observed</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="44" segment_no="8" tag_type="text">that the more vascular the hepatic tumour on angiogram,</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="45" segment_no="8" tag_type="text">the better the prognosis following hepatic artery ligation</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="46" segment_no="8" tag_type="text">and infusional chemotherapy [20]. Subsequently, a</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="47" segment_no="8" tag_type="text">number of authors [8-10] described a correlation between</text>
<text top="603" left="55" width="241" height="10" font="font4" id="p1_t24" reading_order_no="48" segment_no="8" tag_type="text">perfusion of CRC liver metastases, measured by 99m Tc-</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="49" segment_no="8" tag_type="text">MAA scans, and response to HAC. They concluded that<a href="">herapy [20</a>]. Subsequently, a</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="50" segment_no="8" tag_type="text">increased tumour perfusion allows for a higher response<a href="">thors [8-10</a>] described a correlation between</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="51" segment_no="8" tag_type="text">rate from this particular treatment modality. Lehner et al</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="52" segment_no="8" tag_type="text">on the other hand, found no correlation between tumour</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="53" segment_no="8" tag_type="text">vascularity, as indicated by 99m Tc-MAA scan, and response</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="54" segment_no="8" tag_type="text">or survival following HAC in a study involving 36 patients</text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="55" segment_no="8" tag_type="text">with CRC liver metastases. They suggested that the degree</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="56" segment_no="8" tag_type="text">of neo-vascularisation may only be demonstrated by</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="57" segment_no="8" tag_type="text">super-selective catheterisation and questioned whether</text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="58" segment_no="8" tag_type="text">perfusion studies by angiogram or 99m Tc-MAA reliably</text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t35" reading_order_no="59" segment_no="2" tag_type="text">reproduce the perfusion pattern produced by the much</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t36" reading_order_no="60" segment_no="2" tag_type="text">slower flow rate used for chemotherapy [11]. In a rela-</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t37" reading_order_no="61" segment_no="2" tag_type="text">tively recent publication Dancey et al reported a better</text>
<text top="122" left="313" width="241" height="9" font="font4" id="p1_t38" reading_order_no="62" segment_no="2" tag_type="text">response of non-resectable HCC to SIRT with Theras-</text>
<text top="133" left="313" width="241" height="10" font="font4" id="p1_t39" reading_order_no="63" segment_no="2" tag_type="text">pheres ® for patients with "hot" lesions on MAA scan, than</text>
<text top="145" left="313" width="128" height="9" font="font4" id="p1_t40" reading_order_no="64" segment_no="2" tag_type="text">those with "cold" lesions [15].</text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t41" reading_order_no="65" segment_no="4" tag_type="text">The present study relates to SIRT in CRC metastases and</text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t42" reading_order_no="66" segment_no="4" tag_type="text">has adopted a more methodical approach to assessing the</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t43" reading_order_no="67" segment_no="4" tag_type="text">question than that taken in Dancey's report of SIRT in</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t44" reading_order_no="68" segment_no="4" tag_type="text">HCC, and includes a larger number of patients. Not only</text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t45" reading_order_no="69" segment_no="4" tag_type="text">have we attempted to quantify the MAA uptake more pre-<a href="">[11]. I</a>n a rela-</text>
<text top="228" left="313" width="241" height="9" font="font4" id="p1_t46" reading_order_no="70" segment_no="4" tag_type="text">cisely, but we have also attempted to quantify the tumour</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t47" reading_order_no="71" segment_no="4" tag_type="text">response more precisely using changes in tumour marker</text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t48" reading_order_no="72" segment_no="4" tag_type="text">after SIRT. The findings are clear. With the doses used</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t49" reading_order_no="73" segment_no="4" tag_type="text">there is no correlation between MAA uptake into CRC</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t50" reading_order_no="74" segment_no="4" tag_type="text">liver metastases prior to SIRT (TNR) and response to the</text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t51" reading_order_no="75" segment_no="4" tag_type="text">treatment in terms of tumour marker data, CT data or sur-<a href=""> lesions [15].</a></text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t52" reading_order_no="76" segment_no="4" tag_type="text">vival time. Intuitively, one might have expected the oppo-</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t53" reading_order_no="77" segment_no="4" tag_type="text">site finding. The most obvious implication of this is that</text>
<text top="321" left="313" width="241" height="10" font="font4" id="p1_t54" reading_order_no="78" segment_no="4" tag_type="text">the doses of SIR-spheres ® being administered may be</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t55" reading_order_no="79" segment_no="4" tag_type="text">higher than is required for obtaining a response in most</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t56" reading_order_no="80" segment_no="4" tag_type="text">patients. This possibility should be investigated. Compar-</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t57" reading_order_no="81" segment_no="4" tag_type="text">ison between the findings of our and Dancey's study sug-</text>
<text top="368" left="313" width="241" height="10" font="font4" id="p1_t58" reading_order_no="82" segment_no="4" tag_type="text">gests a higher dose of 90 Y microspheres is required for</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="83" segment_no="4" tag_type="text">therapeutic effect in HCC than CRC. The fact that the SIR-</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t60" reading_order_no="84" segment_no="4" tag_type="text">spheres ® were administered to the patients after giving</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="85" segment_no="4" tag_type="text">angiotensin 2 into the hepatic artery, whereas the MAA</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="86" segment_no="4" tag_type="text">perfusion scans were performed without angiotensin 2,</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="87" segment_no="4" tag_type="text">potentially confounds the results and is unfortunately a</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="88" segment_no="4" tag_type="text">weakness arising out of the retrospective nature of the</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="89" segment_no="4" tag_type="text">study. The vasoconstriction achieved by angiotensin 2 has</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="90" segment_no="4" tag_type="text">been shown to assist selective tumour uptake [21] and</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="91" segment_no="4" tag_type="text">provides the theoretical basis for its use. Most units deliv-</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="92" segment_no="4" tag_type="text">ering SIRT do not use angiotensin 2 as it is no longer read-</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="93" segment_no="4" tag_type="text">ily available and this does not obviously compromise</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t70" reading_order_no="94" segment_no="4" tag_type="text">results. The authors feel it is unlikely that the lack of cor-</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="95" segment_no="4" tag_type="text">relation between TNR uptake of MAA and tumour</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="96" segment_no="4" tag_type="text">response to SIRT would be accounted for by the adminis-</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="97" segment_no="4" tag_type="text">tration of angiotensin 2, but it remains a possibility. If a</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="98" segment_no="4" tag_type="text">positive correlation between the pattern of MAA uptake</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="99" segment_no="4" tag_type="text">and tumour response was subsequently shown by another</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="100" segment_no="4" tag_type="text">group, not using angiotensin 2, an argument might be</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="101" segment_no="4" tag_type="text">raised supporting the routine use of a vasoconstrictor dur-</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="102" segment_no="4" tag_type="text">ing SIRT. We currently use a bolus dose of phenylephrine</text>
<text top="613" left="313" width="242" height="13" font="font4" id="p1_t79" reading_order_no="103" segment_no="4" tag_type="text">hydrochloride 100 µ g in lieu of angiotensin 2, on the</text>
<text top="627" left="313" width="236" height="9" font="font4" id="p1_t80" reading_order_no="104" segment_no="4" tag_type="text">grounds this may be of value, and no harm is conferred.</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t81" reading_order_no="105" segment_no="9" tag_type="text">We have observed and previously reported that patients</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t82" reading_order_no="106" segment_no="9" tag_type="text">receiving SIRT using the dosing schedule of the present</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="107" segment_no="9" tag_type="text">study suffer profound lethargy and anorexia for up to 4–6<a href="">selective tumour uptake [21] </a>and</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t84" reading_order_no="108" segment_no="9" tag_type="text">weeks after the treatment [2]. The present study provides</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="109" segment_no="9" tag_type="text">data to indicate that damage is sustained by normal hepa-</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="110" segment_no="9" tag_type="text">tocytes, as indicated by a significant transaminase rise,</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="111" segment_no="9" tag_type="text">after SIRT. There is however, no indication that the extent</text>
<text top="284" left="55" width="226" height="9" font="font7" id="p1_t88" reading_order_no="23" segment_no="5" tag_type="title">Kaplan-Meier survival curves for Group 1 patients ("hot"</text>
<text top="284" left="55" width="237" height="9" font="font7" id="p1_t89" reading_order_no="24" segment_no="5" tag_type="title">lesions) and Group 2 patients ("equivocal" or "cold" lesions)</text>
<text top="284" left="55" width="37" height="9" font="font8" id="p1_t90" reading_order_no="22" segment_no="5" tag_type="title">Figure 5</text>
<text top="294" left="55" width="226" height="9" font="font9" id="p1_t91" reading_order_no="25" segment_no="6" tag_type="text">Kaplan-Meier survival curves for Group 1 patients ("hot"</text>
<text top="305" left="55" width="241" height="9" font="font9" id="p1_t92" reading_order_no="26" segment_no="6" tag_type="text">lesions) and Group 2 patients ("equivocal" or "cold" lesions).</text>
<text top="316" left="55" width="227" height="9" font="font9" id="p1_t93" reading_order_no="27" segment_no="6" tag_type="text">There is no statistical difference in cumulative survival by</text>
<text top="327" left="55" width="49" height="9" font="font9" id="p1_t94" reading_order_no="28" segment_no="6" tag_type="text">logrank test.</text>
<text top="265" left="164" width="69" height="7" font="font10" id="p1_t95" reading_order_no="21" segment_no="3" tag_type="figure">Survival Time (months)</text>
<text top="205" left="63" width="0" height="7" font="font11" id="p1_t96" reading_order_no="6" segment_no="3" tag_type="figure">Cumul</text>
<text top="165" left="63" width="0" height="28" font="font11" id="p1_t97" reading_order_no="5" segment_no="3" tag_type="figure">rop P e iv at</text>
<text top="155" left="63" width="0" height="7" font="font11" id="p1_t98" reading_order_no="4" segment_no="3" tag_type="figure">ort</text>
<text top="132" left="63" width="0" height="22" font="font11" id="p1_t99" reading_order_no="3" segment_no="3" tag_type="figure">ur S n io</text>
<text top="111" left="63" width="0" height="21" font="font11" id="p1_t100" reading_order_no="2" segment_no="3" tag_type="figure">g n vi vi</text>
<text top="246" left="89" width="3" height="7" font="font12" id="p1_t101" reading_order_no="12" segment_no="3" tag_type="figure">0</text>
<text top="246" left="121" width="6" height="7" font="font12" id="p1_t102" reading_order_no="13" segment_no="3" tag_type="figure">12</text>
<text top="246" left="154" width="6" height="7" font="font12" id="p1_t103" reading_order_no="14" segment_no="3" tag_type="figure">24<a href=""> [2]</a>. The present study provides</text>
<text top="246" left="187" width="6" height="7" font="font12" id="p1_t104" reading_order_no="15" segment_no="3" tag_type="figure">36</text>
<text top="246" left="221" width="6" height="7" font="font12" id="p1_t105" reading_order_no="16" segment_no="3" tag_type="figure">48</text>
<text top="246" left="254" width="6" height="7" font="font12" id="p1_t106" reading_order_no="17" segment_no="3" tag_type="figure">60</text>
<text top="246" left="287" width="6" height="7" font="font12" id="p1_t107" reading_order_no="18" segment_no="3" tag_type="figure">72</text>
<text top="240" left="76" width="11" height="7" font="font12" id="p1_t108" reading_order_no="11" segment_no="3" tag_type="figure">0.00</text>
<text top="202" left="76" width="11" height="7" font="font12" id="p1_t109" reading_order_no="10" segment_no="3" tag_type="figure">0.25<b>Figure 5</b></text>
<text top="164" left="76" width="11" height="7" font="font12" id="p1_t110" reading_order_no="9" segment_no="3" tag_type="figure">0.50</text>
<text top="126" left="76" width="11" height="7" font="font12" id="p1_t111" reading_order_no="8" segment_no="3" tag_type="figure">0.75</text>
<text top="88" left="76" width="11" height="7" font="font12" id="p1_t112" reading_order_no="7" segment_no="3" tag_type="figure">1.00</text>
<text top="95" left="261" width="17" height="6" font="font13" id="p1_t113" reading_order_no="19" segment_no="3" tag_type="figure">Group 1</text>
<text top="106" left="261" width="17" height="6" font="font13" id="p1_t114" reading_order_no="20" segment_no="3" tag_type="figure">Group 2<b>Survival Time (months)</b></text>
</page>
</pdf2xml>
